X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 15.4 29.6 52.1% View Chart
P/BV x 2.8 2.5 111.7% View Chart
Dividend Yield % 0.4 0.5 74.5%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
SUN PHARMA
Mar-18
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs930701 132.8%   
Low Rs517433 119.4%   
Sales per share (Unadj.) Rs322.6110.4 292.2%  
Earnings per share (Unadj.) Rs28.511.0 259.5%  
Cash flow per share (Unadj.) Rs39.217.2 227.5%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.4 78.3%  
Book value per share (Unadj.) Rs183.0158.8 115.2%  
Shares outstanding (eoy) m282.172,399.26 11.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.1 43.7%   
Avg P/E ratio x25.451.6 49.2%  
P/CF ratio (eoy) x18.532.9 56.1%  
Price / Book Value ratio x4.03.6 110.8%  
Dividend payout %7.018.2 38.5%   
Avg Mkt Cap Rs m204,2061,360,021 15.0%   
No. of employees `00013.717.8 77.1%   
Total wages/salary Rs m18,71853,671 34.9%   
Avg. sales/employee Rs Th6,636.814,890.9 44.6%   
Avg. wages/employee Rs Th1,364.73,017.1 45.2%   
Avg. net profit/employee Rs Th586.11,480.6 39.6%   
INCOME DATA
Net Sales Rs m91,031264,895 34.4%  
Other income Rs m9148,388 10.9%   
Total revenues Rs m91,945273,282 33.6%   
Gross profit Rs m16,15456,081 28.8%  
Depreciation Rs m3,01914,998 20.1%   
Interest Rs m2,8565,176 55.2%   
Profit before tax Rs m11,19344,295 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m3,1558,452 37.3%   
Profit after tax Rs m8,03926,338 30.5%  
Gross profit margin %17.721.2 83.8%  
Effective tax rate %28.219.1 147.7%   
Net profit margin %8.89.9 88.8%  
BALANCE SHEET DATA
Current assets Rs m69,887316,359 22.1%   
Current liabilities Rs m32,879198,643 16.6%   
Net working cap to sales %40.744.4 91.5%  
Current ratio x2.11.6 133.5%  
Inventory Days Days8195 85.9%  
Debtors Days Days93108 86.8%  
Net fixed assets Rs m28,892213,178 13.6%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m51,353378,606 13.6%   
Net worth Rs m51,635381,006 13.6%   
Long term debt Rs m41,41817,721 233.7%   
Total assets Rs m125,954643,028 19.6%  
Interest coverage x4.99.6 51.5%   
Debt to equity ratio x0.80 1,724.6%  
Sales to assets ratio x0.70.4 175.4%   
Return on assets %8.64.9 176.5%  
Return on equity %15.66.9 225.2%  
Return on capital %15.110.0 150.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31740,816 89.0%   
Fx outflow Rs m9,72030,143 32.2%   
Net fx Rs m26,59810,673 249.2%   
CASH FLOW
From Operations Rs m16,48139,072 42.2%  
From Investments Rs m-10,133-33,708 30.1%  
From Financial Activity Rs m-4,685-15,393 30.4%  
Net Cashflow Rs m1,770-7,359 -24.1%  

Share Holding

Indian Promoters % 48.3 63.7 75.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.1 134.5%  
FIIs % 34.4 23.0 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   56,727 133,026 42.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 14, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - MERCK COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS